Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Die Highlights vom Kongress des American College of Cardiology 2024

Im April diskutierten die Herz-Kreislauf-Spezialisten aus der ganzen Welt auf dem  Kongress des American College of Cardiology (ACC) u.a. neue Therapieansätze bei akutem Myokardinfarkt, koronarer Herzerkrankung, kardiogenem Schock oder Aortenklappenstenose. In unserem Kongress-Dossier haben wir für Sie Berichte über die „Late-Breaking Trials“ und andere wichtige Studien zusammengestellt. 
Erweiterte Suche
Anmelden
nach oben
American Journal of Clinical Dermatology
Erschienen in: American Journal of Clinical Dermatology 4/2009

01.08.2009 | Review Article

Impact of Topical Calcineurin Inhibitors on Quality of Life in Patients with Atopic Dermatitis

verfasst von: Dr John R. Ingram, Julie A. Martin, Andrew Y. Finlay

Erschienen in: American Journal of Clinical Dermatology | Ausgabe 4/2009

Einloggen, um Zugang zu erhalten

Abstract

This review considers randomized trials of topical calcineurin inhibitors in atopic dermatitis that have included quality-of-life (QOL) data. Relatively few trials were identified and several different QOL measures have been used, partly because trial subjects included adults, children, and the parents of affected infants. Tacrolimus 0.1% and 0.03% ointment and pimecrolimus 1% cream were found to be superior to vehicle treatment in terms of QOL for active AD. In adults, tacrolimus 0.1% ointment provided a greater improvement in QOL than the 0.03% strength. Pimecrolimus 1% cream was superior to vehicle treatment for flare prevention in the studies that contained QOL outcomes but no data are available for tacrolimus ointment in this regard. QOL data comparing topical calcineurin inhibitors with other active treatments such as topical corticosteroids are sparse and it would be useful for future randomized trials to include QOL measures as a primary outcome.
Literatur
1.
Wollenberg A, Bieber T. Atopic dermatitis: from the genes to skin lesions. Allergy 2000; 55: 205–13PubMedCrossRef
2.
Williams HC, Wuethrich B. The natural history of atopic dermatitis. In: Williams HC, editor. Atopic dermatitis: the epidemiology, causes and prevention of atopic eczema. Cambridge: Cambridge University Press, 2000: 41–59CrossRef
3.
The International Study of Asthma and Allergies in Childhood (ISAAC). Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema: ISAAC. Lancet 1998; 351: 225–32
4.
Diepgen TL, Blettner M. Analysis of familial aggregation of atopic eczema and other atopic diseases by ODDS RATIO regression models. J Invest Dermatol 1996; 106: 977–81PubMedCrossRef
5.
Larsen FS, Holm NV, Henningen K. Atopic dermatitis: a geneticepidemiologic study in a population-based twin sample. J Am Acad Dermatol 1986; 15: 487–94PubMedCrossRef
6.
Williams HC, Pembroke AC, Forsdyke H, et al. London-born black Caribbean children are at increased risk of atopic dermatitis. J Am Acad Dermatol 1995; 32: 2120–7CrossRef
7.
Beattie PE, Lewis-Jones MS. A comparative study of impairment of quality of life (QOL) in children with skin disease and children with other chronic childhood diseases. Br J Dermatol 2006; 155: 145–55PubMedCrossRef
8.
Emerson RM, Williams HC, Allen BR. What is the cost of atopic dermatitis in pre-school children? Br J Dermatol 2001; 143: 514–22CrossRef
9.
Ellis CN, Drake LA, Prendergast MM, et al. Cost of atopic dermatitis and eczema in the United States. J Am Acad Dermatol 2002; 46: 361–70PubMedCrossRef
10.
Finlay AY. Quality of life in atopic dermatitis. J Am Acad Dermatol 2001; 45 Suppl. 1: S67–8
11.
Lewis-Jones MS, Finlay AY. The children’s dermatology life quality index (CDLQI): initial validation and practical use. Br J Dermatol 1995; 132: 942–9PubMedCrossRef
12.
Lawson V, Lewis-Jones MS, Finlay AY, et al. The family impact of childhood atopic dermatitis: the Dermatitis Family Impact questionnaire. Br J Dermatol 1998; 138: 107–13PubMedCrossRef
13.
Lundberg L, Johannesson M, Silverdahl M, et al. Health-related quality of life in patients with psoriasis and atopic dermatitis measured with SF-36, DLQI and a subjective measure of disease activity. Acta Derm Venereol (Stockh) 2000; 80: 430–4CrossRef
14.
Finlay AY. Quality of life impairment in atopic dermatitis and psoriasis. Clin Exp Perspect Sandimmun Ther 1992; 2: 10–11
15.
Basra MK, Finlay AY. The family impact of skin diseases: the Greater Patient concept. Br J Dermatol 2007; 156: 929–37PubMedCrossRef
16.
Whally D, McKenna SP. The impact of childhood atopic dermatitis on the quality of life of the family. PCI J Progress Clin Insights 1999; 7: 10–11
17.
Elliot B. Itching agony. Nurs Times 1990; 86: 72
18.
Daud LR, Garralda ME, David TJ. Psychosocial adjustment in preschool children with atopic eczema. Arch Dis Child 1993; 69: 670–6PubMedCrossRef
19.
Finlay AY. Quality of life assessments in dermatology. Semin Cutan Med Surg 1998; 17: 291–6PubMedCrossRef
20.
Elliot BE, Luker K. The experiences of mothers caring for a child with severe atopic eczema. J Clin Nurs 1997; 6: 241–7CrossRef
21.
22.
Holme SA, Man I, Sharpe JL, et al. The Children’s Dermatology Life Quality Index: validation of the cartoon version. Br J Dermatol 2003; 148: 285–90PubMedCrossRef
23.
Charman C, Chambers C, Williams H. Measuring atopic dermatitis severity in randomised controlled clinical trials: what exactly are we measuring? J Invest Dermatol 2003; 120: 932–41PubMedCrossRef
24.
European Task Force on Atopic Dermatitis. Severity scoring of atopic dermatitis; the SCORAD index. Dermatology 1993; 186: 23–31
25.
Ben-Gashir MA, Seed PT, Hay RJ. Quality of life and disease severity are correlated in children with atopic dermatitis. Br J Dermatol 2004; 150: 284–90PubMedCrossRef
26.
Ben-Gashir MA, Seed PT, Hay RJ. Are quality of family life and disease severity related in childhood atopic dermatitis? J Eur Acad Dermatol Venereol 2002; 16: 455–62PubMedCrossRef
27.
Hanifin JM, Thurston M, Omoto M, et al. The Eczema Area and Severity Index (EASI): assessment of reliability in atopic dermatitis. Clin Exp Dermatol 2001; 10: 11–8
28.
Touw CR, Kakkaari-Van Roijen L, Verboom P, et al. Quality of life and clinical outcome in psoriasis using intermittent ciclosporin. Br J Dermatol 2001; 144: 967–72PubMedCrossRef
29.
Wahl A, Burckhardt C, Wiklund I, et al. The Norwegian version of the Quality of Life Scale (QOLS-N): a validation and reliability study in patients suffering from psoriasis. Scand J Caring Sci 1998; 12: 215–22PubMedCrossRef
30.
Charman CR, Morris AD, Williams HC. Topical corticosteroid phobia in patients with atopic eczema. Br J Dermatol 2000; 142: 931–6PubMedCrossRef
31.
Berth-Jones J, Damstra RJ, Golsch S, et al. Twice weekly fluticasone propionate added to emollient maintenance treatment to reduce risk of relapse in atopic dermatitis: randomised, double-blind, parallel group study. BMJ 2003; 326: 1367–72PubMedCrossRef
32.
Liu J, Albers MW, Wandless TJ, et al. Inhibition of T-cell signalling by immunophilin-ligand complexes correlates with loss of calcineurin phosphatase activity. Biochemistry 1992; 31: 3896–901PubMedCrossRef
33.
Grassberger M, Baumruker T, Enz A, et al. A novel anti-inflammatory drug, SDZ ASM 981, for the treatment of skin diseases: in vitro pharmacology. Br J Dermatol 1999; 141: 264–73PubMedCrossRef
34.
Kino T, Hatanaka H, Hashimoto M, et al. FK-506, a novel immunosuppressant isolated from a Streptomyces: I. Fermentation, isolation, and physico-chemical and biological characteristics. J Antibiot (Tokyo) 1987; 40: 1249–55CrossRef
35.
Hanifin JM, Ling MR, Langley R, et al. Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part I, efficacy. J Am Acad Dermatol 2001; 44: S28–38CrossRef
36.
Soter NA, Fleischer Jr AB, Webster GF, et al. Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part II, safety. J Am Acad Dermatol 2001; 44: S39–46CrossRef
37.
Paller A, Eichenfield LF, Leung DYM, et al. A 12-week study of tacrolimus ointment for the treatment of atopic dermatitis in pediatric patients. J Am Acad Dermatol 2001; 44: S44–57CrossRef
38.
Boguniewicz M, Fiedler VC, Raimer S, et al. A randomized, vehicle-controlled trial of tacrolimus ointment for the treatment of atopic dermatitis in children. J Allergy Clin Immunol 1998; 102: 637–44PubMedCrossRef
39.
Reitamo S, Van Leent EJM, Ho V, et al. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone acetate ointment in children with atopic dermatitis. J Allergy Clin Immunol 2002; 109: 539–46PubMedCrossRef
40.
Reitamo S, Harper J, Bos JD, et al. 0.03% tacrolimus ointment applied once or twice daily is more efficacious than 1% hydrocortisone acetate in children with moderate to severe atopic dermatitis: results of a randomized double-blind controlled trial. Br J Dermatol 2004; 150: 554–62PubMedCrossRef
41.
Reitamo S, Ortonne JP, Sand C, et al. A multicentre, randomized, doubleblind, controlled study of long-term treatment with 0.1% tacrolimus ointment in adults with moderate to severe atopic dermatitis. Br J Dermatol 2005; 152: 1282–9PubMedCrossRef
42.
Kang S, Lucky AW, Pariser D, et al. Long-term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in children. J Am Acad Dermatol 2001; 44: S58–64CrossRef
43.
Hanifin JM, Leung DYM, Paller A, et al. Tacrolimus ointment monotherapy is safe and effective for the long-term treatment (more than 3 years) of atopic dermatitis in pediatric patients [abstract]. J Allergy Clin Immunol 2003; 111: S130CrossRef
44.
Arai T, Koyama Y, Suenaga T, et al. Ascomycin, an anti-fungal antibiotic. J Antibiot Series A 1962; 15: 231–2
45.
Stuetz A, Grassberger M, Meingassner JG. Pimecrolimus (Elidel, SDZ ASM 981). Semin Cutan Med Surg 2001; 20: 233–41PubMedCrossRef
46.
Meingasser JG, Grassberger M, Fahrngruber H, et al. A novel anti-inflammatory drug, SDZ ASM 981, for the topical and oral treatment of skin diseases: in vivo pharmacology. Br J Dermatol 1997; 137: 569–76
47.
Hultsch T, Muller KD, Meingasser JG, et al. Ascomycin macrolactam derivative SDZ ASM 981 inhibits the release of granule-associated mediators and of newly synthesized cytokines in RBL 2H3 mast cells in an immunophilindependant manner. Arch Dermatol Res 1998; 290: 501–7PubMedCrossRef
48.
Eichenfield LF, Lucky AW, Boguniewicz M, et al. Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild to moderate atopic dermatitis in children and adolescents. J Am Acad Dermatol 2002; 46: 495–504PubMedCrossRef
49.
Ho VC, Gupta A, Kaufmann R, et al. Safety and efficacy of non-steroid pimecrolimus cream 1% in the treatment of atopic dermatitis in infants. J Pediatr 2003; 142: 155–62PubMedCrossRef
50.
Wahn U, Bos JD, Goodfield M, et al. Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. Pediatrics 2002; 110: e2–9CrossRef
51.
Meurer M, Föster-Holst R, Wozel G, et al. Pimecrolimus cream in the long-term management of atopic dermatitis in adults: a six-month study. Dermatology 2002; 205: 271–7PubMedCrossRef
52.
Kapp A, Papp K, Bingham A, et al. Long-term management of atopic dermatitis in infants with topical pimecrolimus, a non-steroid anti-inflammatory drug. J Allergy Clin Immunol 2002; 110: 277–84PubMedCrossRef
53.
Queille-Roussel C, Paul C, Duteil L, et al. The new topical ascomycin derivative SDZ ASM 981 does not induce skin atrophy when applied to normal skin for 4 weeks: a randomised, double-blind, controlled study. Br J Dermatol 2001; 144: 507–13PubMedCrossRef
54.
Kyllonen H, Remitz A, Mandelin JM, et al. Effects of 1 year intermittent treatment with topical tacrolimus monotherapy on skin collagen synthesis in patients with atopic dermatitis. Br J Dermatol 2004; 150: 1174–81PubMedCrossRef
55.
Naylor M, Elmets C, Jarracz E, et al. Non-melanoma skin cancer in patients with atopic dermatitis treated with topical tacrolimus. J Dermatol Treat 2005; 16: 149–53CrossRef
56.
Rustin MH. The safety of tacrolimus ointment for the treatment of atopic dermatitis: a review. Br J Dermatol 2007; 157: 861–73PubMedCrossRef
57.
Ashcroft DM, Chen L-C, Garside R, et al. Topical pimecrolimus for eczema. Cochrane Database Syst Rev 2007; (4): CD005500
58.
Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI): a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19: 210–6PubMedCrossRef
59.
Smith CH, Anstey AV, Barker JN, et al. British Association of Dermatologists guidelines for use of biological interventions in psoriasis 2005. Br J Dermatol 2005; 153: 486–97PubMedCrossRef
60.
Kawashima M, QOL Research Forum for Patients with Atopic Dermatitis. Quality of life in patients with atopic dermatitis: impact of tacrolimus ointment. Int J Dermatol 2006; 45: 731–6
61.
Won CH, Seo PG, Park YM, et al. A multicenter trial of the efficacy and safety of 0.03% tacrolimus ointment for atopic dermatitis in Korea. J Dermatol Treat 2004; 15: 30–4CrossRef
62.
Singalavanija S, Noppakun N, Limpongsanuruk W, et al. Efficacy and safety of tacrolimus ointment in pediatric patients with moderate to severe atopic dermatitis. J Med Assoc Thai 2006; 89: 1915–22PubMed
63.
Sunderkotter C, Weiss JM, Bextermoller R, et al. Post-marketing surveillance on treatment of 5,665 patients with atopic dermatitis using the calcineurin inhibitor pimecrolimus: positive effects on major symptoms of atopic dermatitis and on quality of life. J Dtsch Dermatol Ges 2006; 4: 301–6PubMedCrossRef
64.
Hongbo Y, Thomas CL, Harrison MA, et al. Translating the science of quality of life into practice: what do dermatology life quality index scores mean? J Invest Dermatol 2005; 125: 659–64PubMedCrossRef
65.
Whalley D, McKenna SP, Dewar AL, et al. A new instrument for assessing quality of life in atopic dermatitis: international development of the Quality of Life Index for Atopic Dermatitis (QoLIAD). Br J Dermatol 2004; 150: 274–83PubMedCrossRef
66.
McKenna SP, Whalley D, Dewar AL, et al. International development of the Parents’ Index of Quality of Life in Atopic Dermatitis (PIQoL-AD). Qual Life Res 2005; 14: 231–41PubMedCrossRef
67.
Staab D, Kaufmann R, Brautigam M, et al. Treatment of infants with atopic eczema with pimecrolimus cream 1% improves parents’ quality of life: a multicenter, randomized trial: CASM981CDE04-Study Group. Pediatr Allergy Immunol 2005; 16: 527–33PubMedCrossRef
68.
McKenna SP, Doward LC, Meads DM, et al. Quality of life in infants and children with atopic dermatitis: addressing issues of differential item functioning across countries in multinational clinical trials. Health Qual Life Outcomes 2007; 5: 45PubMedCrossRef
69.
Hunt SM, McKenna SP. The QLDS: a scale for the measurement of quality of life in depression. Health Policy 1992; 22: 307–19PubMedCrossRef
70.
Drake L, Prendergast M, Maher R, et al. The impact of tacrolimus ointment on health-related quality of life of adult and pediatric patients with atopic dermatitis. J Am Acad Dermatol 2001; 44: S65–72CrossRef
71.
Whalley D, Huels J, McKenna SP, et al. The benefit of pimecrolimus (Elidel, SDZ ASM 981) on parents’ quality of life in the treatment of pediatric atopic dermatitis. Pediatrics 2002; 110: 1133–6PubMedCrossRef
72.
Leo HL, Bender BG, Leung SB, et al. Effect of pimecrolimus cream 1% on skin condition and sleep disturbance in children with atopic dermatitis. J Allergy Clin Immunol 2004; 114: 691–3PubMedCrossRef
73.
Bieber T, Vick K, Folster-Holst R, et al. Efficacy and safety of methylprednisolone aceponate ointment 0.1% compared to tacrolimus 0.03% in children and adolescents with an acute flare of severe atopic dermatitis. Allergy 2007; 62: 184–9PubMedCrossRef
74.
McKenna SP, Whalley D, de Prost Y, et al. Treatment of paediatric atopic dermatitis with pimecrolimus (Elidel, SDZ ASM 981): impact on quality of life and health-related quality of life. J Eur Acad Dermatol Venereol 2006; 20: 248–54PubMedCrossRef
75.
Meads DM, McKenna SP, Kahler K. The quality of life of parents of children with atopic dermatitis: interpretation of PIQoL-AD scores. Qual Life Res 2005; 14: 2235–45PubMedCrossRef
76.
Meurer M, Fartasch M, Albrecht G, et al. Long-term efficacy and safety of pimecrolimus cream 1% in adults with moderate atopic dermatitis. Dermatology 2004; 208: 365–72PubMedCrossRef
77.
Ashcroft DM, Dimmock P, Garside R, et al. Efficacy and tolerability of topical pimecrolimus and tacrolimus in the treatment of atopic dermatitis: meta-analysis of randomized controlled trials. BMJ 2005; 330: 516PubMedCrossRef
Metadaten
Titel
Impact of Topical Calcineurin Inhibitors on Quality of Life in Patients with Atopic Dermatitis
verfasst von
Dr John R. Ingram
Julie A. Martin
Andrew Y. Finlay
Publikationsdatum
01.08.2009
Verlag
Springer International Publishing
Erschienen in
American Journal of Clinical Dermatology / Ausgabe 4/2009
Print ISSN: 1175-0561
Elektronische ISSN: 1179-1888
DOI
https://doi.org/10.2165/00128071-200910040-00003

Weitere Artikel der Ausgabe 4/2009

American Journal of Clinical Dermatology 4/2009 Zur Ausgabe

Case Reports

Basal Cell Carcinoma Presenting Late in a Shotgun Scar

Review Article

Dapsone 5% Gel

Case Reports

Vitiligo Koebnerized by Behçet Disease Genital Ulceration

Review Article

Acute Urticaria and Angioedema

Review Article

The Role of Topical Retinoids in the Treatment of Pigmentary Disorders

Therapy in Practice

Toenail Onychomycosis in Diabetic Patients

Leitlinien kompakt für die Dermatologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Dermatologie

Riesenzellarteriitis: 15% der Patienten sind von okkulter Form betroffen

16.05.2024 Riesenzellarteriitis Nachrichten

In einer retrospektiven Untersuchung haben Forschende aus Belgien und den Niederlanden die okkulte Form der Riesenzellarteriitis genauer unter die Lupe genommen. In puncto Therapie und Rezidivraten stellten sie keinen sehr großen Unterschied zu Erkrankten mit kranialen Symptomen fest.

Betalaktam-Allergie: praxisnahes Vorgehen beim Delabeling

16.05.2024 Pädiatrische Allergologie Nachrichten

Die große Mehrheit der vermeintlichen Penicillinallergien sind keine. Da das „Etikett“ Betalaktam-Allergie oft schon in der Kindheit erworben wird, kann ein frühzeitiges Delabeling lebenslange Vorteile bringen. Ein Team von Pädiaterinnen und Pädiatern aus Kanada stellt vor, wie sie dabei vorgehen.

Isotretinoin: Risiko für schwere Laboranomalien „marginal erhöht“

08.05.2024 Akne Nachrichten

Die Aknetherapie mit Isotretinoin kann einen Anstieg von Leberenzymen und Blutfetten verursachen. Das Risiko für schwere Störungen ist laut einer Forschungsgruppe der Universität Lübeck aber nur marginal erhöht und auf einen engen Zeitraum konzentriert.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Update Dermatologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise